MPXA-2000
Overview
Medipixel is a global healthcare company dedicated to improving the quality of human life by applying advanced AI technology to healthcare. Their primary focus is on revolutionizing diagnostic and treatment protocols within the cardiovascular field, with an expanding interest in neurovascular care. The flagship product, MPXA-2000, is an AI-based software medical device designed for the comprehensive analysis of cardiovascular angiography images.
MPXA-2000 seamlessly integrates into the cath lab workflow, providing real-time, automated quantitative analysis of coronary artery stenotic lesions. Utilizing cutting-edge deep learning and computer vision algorithms, it performs vessel segmentation and calculates precise dimensions, offering measurements comparable to those obtained through intravascular ultrasound (IVUS). This tool supports cardiologists and radiologists in making informed clinical decisions, evaluating interventions, and assessing drug therapies for adult patients with coronary artery disease (CAD).
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Automatic analysis of 2D angiography images
- AI algorithm for quantifying coronary artery stenotic lesions
- Provides measurements similar to intravascular ultrasound (IVUS)
- Real-time analysis of cardiovascular condition
- Supports clinicians in decision-making during PCI
- Vessel segmentation and lesion analysis
- Highly accurate quantitative analysis
- Compatible with DICOM standard X-ray angiographic images from Philips Medical Systems, Siemens Healthineers, GE Healthcare
Use Cases
- Supporting clinical decisions concerning coronary arteries
- Evaluating intervention or drug therapy for coronary artery conditions
- Quantitative analysis of cardiovascular images in cath labs
- Assisting in stent sizing during PCI procedures
What Physicians Need to Know
MPXA-2000 offers real-time, AI-powered quantitative analysis of coronary angiography images, which can significantly reduce the limitations of visual estimation and inter-observer variability in the cath lab. The rapid analysis and automated features, such as vessel segmentation and lesion quantification, can enhance procedural efficiency and support faster, more objective treatment decisions during PCI. The ability to recommend optimal stent location, length, and diameter based on accurate ROI analysis can further aid in procedural planning. This tool has been shown to achieve comparable outcomes to OCT in cardiovascular procedures, offering a potentially simpler and faster workflow.
MPXA-2000 integrates into the cath lab workflow by processing DICOM contrast images in real-time during cardiovascular imaging. It supports various output formats for result reports, including Excel, PDF, and DICOM (scheduled support), enhancing usability in medical settings.
Details
| Category | Cardiology AI |
| Pricing | Unknown |
| Deployment | Stand-alone application; integrates seamlessly into cath lab workflow |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology |
What the Web Says
MPXA-2000 by Medipixel is an AI-powered software designed for quantitative coronary angiography (QCA) that analyzes 2D angiography images to quantify coronary artery stenotic lesions. It aims to assist physicians in making clinical decisions during percutaneous coronary intervention (PCI) by providing automated, real-time quantitative information. Studies have shown it to have a moderate to strong correlation with intravascular ultrasound (IVUS) and to outperform visual estimation by cardiologists in lesion detection and quantification.
Overall: PositiveStrengths
- Automated and real-time quantitative analysis of coronary angiography images.
- Potential to support clinical decisions and improve patient outcomes.
- Moderate to strong correlation with IVUS for reference vessel size and stenosis severity.
- Superiority over visual estimation by cardiologists in lesion detection and quantification.
- High sensitivity in detecting lesions in major vessels and side branches.
- Potential to reduce healthcare personnel's time by offering consistent lesion identification and analysis.
Limitations
- Moderate correlation for percent area stenosis and lesion length compared to IVUS.
- Tendency to underestimate reference vessel area and mildly atherosclerotic lesions.
- Geographic mismatch in proximal or distal lesion margins compared to IVUS.
- Workflow convenience issues, such as steps for sign-in, image selection, and frame selection, may impede user experience.
- Potential barriers include the need for training and associated costs.
- System Usability Scale (SUS) score of 66.7 indicates marginal high acceptability.
Based on reviews from: jmir.org, researchgate.net, mdpi.com, medium.com, amegroups.org, bdmtglobal.com, healthaidb.com
Last updated: 2026-10-31
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate MPXA-2000
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for MPXA-2000.
[BIOSTAR Interview] uc2ecud608uad00uc9c8ud658 uc2dcuc220uc2e4uc758 ub0b4ube44uac8cuc774uc158
ubcf4uac74uc0b0uc5c5ud601uc2e0ucc3duc5c5uc13cud130 KBIC
